Adrian Gottschalk
Fortuna: 2 M $ al 30/06/2026
Fortuna: 2 M $ al 30/06/2026
Adrian Gottschalk is President, Chief Executive Officer & Director at Foghorn Therapeutics, Inc. since 2017.
Formerly, Mr. Gottschalk was SVP & Head-Neurodegeneration Therapeutic Area at Biogen, Inc. from 2015 to 2017.
Education includes an undergraduate degree from Texas A&M University in 1997, an MBA from MIT Sloan School of Management in 2003, and a graduate degree from Harvard Medical School in 2004.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/04/2026 | 511.704 ( 0,87 % ) | 2 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director Ejecutivo | 01/05/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/05/2017 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Texas A&M University
Texas A&M University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Foghorn Therapeutics, Inc.
Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.